Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Generation of the Niemann-Pick type C2 patient-derived iPSC line AKOSi001-A.

Völkner C, Peter F, Liedtke M, Krohn S, Lindner I, Murua Escobar H, Cimmaruta C, Lukas J, Hermann A, Frech MJ.

Stem Cell Res. 2019 Oct 15;41:101606. doi: 10.1016/j.scr.2019.101606. [Epub ahead of print]

2.

A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.

Barrett CD, Dobos K, Liedtke M, Tuzovic M, Haddad F, Kobayashi Y, Lafayette R, Fowler MB, Arai S, Schrier S, Witteles RM.

JACC Heart Fail. 2019 Nov;7(11):958-966. doi: 10.1016/j.jchf.2019.07.007. Epub 2019 Oct 9.

PMID:
31606365
3.

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R.

J Natl Compr Canc Netw. 2019 Oct 1;17(10):1154-1165. doi: 10.6004/jnccn.2019.0049.

PMID:
31590151
4.

B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.

Eckhert E, Hewitt R, Liedtke M.

Immunotherapy. 2019 Jun;11(9):801-811. doi: 10.2217/imt-2018-0199. Epub 2019 May 16.

PMID:
31094254
5.

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN.

N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.

PMID:
31042825
6.

Therapy-related myeloid neoplasms after treatment for plasma-cell disorders.

Chung A, Liedtke M.

Best Pract Res Clin Haematol. 2019 Mar;32(1):54-64. doi: 10.1016/j.beha.2019.02.003. Epub 2019 Feb 8. Review.

PMID:
30927976
7.

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS.

Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28.

8.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.

9.

An mHealth pilot designed to increase the reach of prevention of mother-to-child transmission of HIV (PMTCT) across the treatment cascade in a resource-constrained setting in Tanzania.

Thomas DSK, Bull S, Nyanza EC, Hampanda K, Liedtke M, Ngallaba SE.

PLoS One. 2019 Feb 15;14(2):e0212305. doi: 10.1371/journal.pone.0212305. eCollection 2019.

10.

Gastroduodenal anastomotic insufficiency: pull-through technique for endoscopic negative pressure therapy with new types of open-pore drains.

Rucktaeschel F, Liedtke M, Schlöricke E, Herrmann T, Loske G.

Endoscopy. 2019 Apr;51(4):E85-E87. doi: 10.1055/a-0824-6130. Epub 2019 Feb 7. No abstract available.

PMID:
30731486
11.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18. Erratum in: Blood. 2019 Sep 26;134(13):1111.

PMID:
30658992
12.

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gökbuget N, Martinelli G, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HM.

Am J Hematol. 2019 Apr;94(4):408-416. doi: 10.1002/ajh.25394. Epub 2019 Jan 17.

PMID:
30623490
13.

Grading cardiac response in AL amyloidosis: implications for relapse and survival.

Eckhert E, Witteles R, Kaufman G, Lafayette R, Arai S, Schrier S, O'Shaughnessy M, Liedtke M.

Br J Haematol. 2019 Jul;186(1):144-146. doi: 10.1111/bjh.15717. Epub 2018 Dec 19. No abstract available.

PMID:
30569572
14.

Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.

Gong CL, Studdert AL, Liedtke M.

Am J Hematol. 2019 Mar;94(3):E68-E70. doi: 10.1002/ajh.25372. Epub 2018 Dec 18. No abstract available.

PMID:
30536952
15.

Antibody-based therapies in patients with acute lymphoblastic leukemia.

Dinner S, Liedtke M.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):9-15. doi: 10.1182/asheducation-2018.1.9. Review.

PMID:
30504286
16.

Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Yurkiewicz IR, Muffly L, Liedtke M.

Drug Des Devel Ther. 2018 Jul 24;12:2293-2300. doi: 10.2147/DDDT.S150317. eCollection 2018. Review.

17.

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, Estevam J, Berg D, Baz R.

Br J Haematol. 2018 Jul;182(2):231-244. doi: 10.1111/bjh.15394. Epub 2018 Jun 25.

18.

Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients.

Yurkiewicz IR, Simon P, Liedtke M, Dahl G, Dunn T.

J Adolesc Young Adult Oncol. 2018 Oct;7(5):579-583. doi: 10.1089/jayao.2018.0022. Epub 2018 Jun 20.

PMID:
29924668
19.

A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.

Dinner S, Dunn TJ, Price E, Coutré SE, Gotlib J, Berube C, Kaufman GP, Medeiros BC, Liedtke M.

Int J Hematol. 2018 Sep;108(3):267-273. doi: 10.1007/s12185-018-2468-5. Epub 2018 May 25.

PMID:
29802551
20.

Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.

Leuk Res. 2018 Apr;67:17-20. doi: 10.1016/j.leukres.2018.01.021. Epub 2018 Jan 31.

21.

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM.

Cancer. 2018 Apr 15;124(8):1722-1732. doi: 10.1002/cncr.31249. Epub 2018 Jan 30.

22.

In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional.

Altrichter S, Hawro T, Liedtke M, Holtappels G, Bachert C, Skov PS, Maurer M.

Allergy. 2018 Jul;73(7):1497-1504. doi: 10.1111/all.13381. Epub 2018 Feb 20.

PMID:
29315616
23.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS.

Blood Adv. 2017 Jun 27;1(15):1167-1180. doi: 10.1182/bloodadvances.2016001925. eCollection 2017 Jun 27.

24.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
25.

Providing Comprehensive Medication Management in Telehealth.

Badowski ME, Walker S, Bacchus S, Bartlett S, Chan J, Cochran KA, Coon S, Liedtke M, Phillips BG, White T.

Pharmacotherapy. 2018 Feb;38(2):e7-e16. doi: 10.1002/phar.2071. Epub 2018 Jan 16. Review.

PMID:
29239004
26.

Clinical implications of gastrointestinal symptoms in systemic amyloidosis.

Yen T, Chen FW, Witteles RM, Liedtke M, Nguyen LA.

Neurogastroenterol Motil. 2018 Apr;30(4):e13229. doi: 10.1111/nmo.13229. Epub 2017 Oct 10.

PMID:
29024324
27.

Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).

Tuzovic M, Kobayashi Y, Wheeler M, Barrett C, Liedtke M, Lafayette R, Schrier S, Haddad F, Witteles R.

Am J Cardiol. 2017 Oct 15;120(8):1381-1386. doi: 10.1016/j.amjcard.2017.07.025. Epub 2017 Jul 25.

PMID:
28844519
28.

Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.

Hansmann L, Han A, Penter L, Liedtke M, Davis MM.

Cancer Immunol Res. 2017 Sep;5(9):744-754. doi: 10.1158/2326-6066.CIR-17-0012. Epub 2017 Aug 2.

29.

Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J, Westervelt P, Merker JD, Berube C, Coutre S, Liedtke M, Medeiros B, Sternberg D, Dutreix C, Ruffie PA, Corless C, Graubert TJ, Gotlib J.

Leukemia. 2018 Feb;32(2):470-478. doi: 10.1038/leu.2017.234. Epub 2017 Jul 24.

PMID:
28744009
30.

Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.

Saygin C, Papadantonakis N, Cassaday RD, Liedtke M, Fischer K, Dunn T, Patel BJ, Sobecks R, Kalaycio M, Sekeres MA, Mukherjee S, Gerds AT, Hamilton BK, Carraway HE, Advani AS.

Leuk Lymphoma. 2018 Feb;59(2):363-371. doi: 10.1080/10428194.2017.1344842. Epub 2017 Jul 11.

PMID:
28693363
31.

Evaluation of the concurrent use of dolutegravir and metformin in human immunodeficiency virus-infected patients.

Masich A, Badowski ME, Liedtke MD, Fulco PP.

Int J STD AIDS. 2017 Oct;28(12):1229-1233. doi: 10.1177/0956462417695995. Epub 2017 Mar 1.

PMID:
28632474
32.

Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.

Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M.

Blood. 2017 Aug 17;130(7):900-902. doi: 10.1182/blood-2017-01-763599. Epub 2017 Jun 14.

PMID:
28615223
33.

Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016.

Maurer M, Lousada I, Hanna M, Ruberg F, Mohty D, Dispenzieri A, Liedtke M, Paulson I, Vest J, Grogan M.

Amyloid. 2017 Mar;24(sup1):165-166. doi: 10.1080/13506129.2017.1286582. No abstract available.

PMID:
28434366
34.

Acute Care Management of the HIV-Infected Patient: A Report from the HIV Practice and Research Network of the American College of Clinical Pharmacy.

Durham SH, Badowski ME, Liedtke MD, Rathbun RC, Pecora Fulco P.

Pharmacotherapy. 2017 May;37(5):611-629. doi: 10.1002/phar.1921. Epub 2017 May 9. Review.

PMID:
28273373
35.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

PMID:
28188192
36.

Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response.

Jiang D, Lynch C, Medeiros BC, Liedtke M, Bam R, Tam AB, Yang Z, Alagappan M, Abidi P, Le QT, Giaccia AJ, Denko NC, Niwa M, Koong AC.

Sci Rep. 2016 Sep 16;6:33353. doi: 10.1038/srep33353.

37.

An antibody that prevents serpin polymerisation acts by inducing a novel allosteric behaviour.

Motamedi-Shad N, Jagger AM, Liedtke M, Faull SV, Nanda AS, Salvadori E, Wort JL, Kay CW, Heyer-Chauhan N, Miranda E, Perez J, Ordóñez A, Haq I, Irving JA, Lomas DA.

Biochem J. 2016 Oct 1;473(19):3269-90. doi: 10.1042/BCJ20160159. Epub 2016 Jul 12.

38.

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS.

N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.

39.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2016 Apr;14(4):389-400.

40.

A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Dunn TJ, Dinner S, Price E, Coutré SE, Gotlib J, Hao Y, Berube C, Medeiros BC, Liedtke M.

Br J Haematol. 2016 Apr;173(2):253-9. doi: 10.1111/bjh.13946. Epub 2016 Apr 4.

PMID:
27040320
41.

HIV Pharmacist's Impact on Inpatient Antiretroviral Errors.

Liedtke MD, Tomlin CR, Skrepnek GH, Farmer KC, Johnson PN, Rathbun RC.

HIV Med. 2016 Nov;17(10):717-723. doi: 10.1111/hiv.12375.

42.

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M.

J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8.

43.

Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature.

Leatham HW, Novoa R, Liedtke M, Kwong BY.

Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):e1-5. doi: 10.1016/j.clml.2015.11.007. Epub 2015 Nov 22. Review. No abstract available.

PMID:
26708980
44.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

45.

CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.

Iwasaki M, Liedtke M, Gentles AJ, Cleary ML.

Cell Stem Cell. 2015 Oct 1;17(4):412-21. doi: 10.1016/j.stem.2015.08.008. Epub 2015 Sep 18.

46.

Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.

Narayan R, Garcia JS, Percival ME, Berube C, Coutre S, Gotlib J, Greenberg P, Liedtke M, Hewitt R, Regan K, Williamson C, Doykan C, Cardone MH, McMillan A, Medeiros BC.

Leuk Lymphoma. 2016;57(3):609-15. doi: 10.3109/10428194.2015.1091930. Epub 2015 Oct 13.

PMID:
26374199
47.

The role of dolutegravir in the management of HIV infection.

Miller MM, Liedtke MD, Lockhart SM, Rathbun RC.

Infect Drug Resist. 2015 Feb 19;8:19-29. doi: 10.2147/IDR.S58706. eCollection 2015. Review.

48.

Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma.

Hansmann L, Blum L, Ju CH, Liedtke M, Robinson WH, Davis MM.

Cancer Immunol Res. 2015 Jun;3(6):650-60. doi: 10.1158/2326-6066.CIR-14-0236-T. Epub 2015 Feb 20.

49.

Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.

Davis MK, Kale P, Liedtke M, Schrier S, Arai S, Wheeler M, Lafayette R, Coakley T, Witteles RM.

Am J Transplant. 2015 Mar;15(3):650-8. doi: 10.1111/ajt.13025. Epub 2015 Feb 3.

50.

Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.

Liedtke M, Dunn T, Dinner S, Coutré SE, Berube C, Gotlib J, Patel S, Medeiros B.

Leuk Res. 2014 Dec;38(12):1441-5. doi: 10.1016/j.leukres.2014.09.018. Epub 2014 Oct 6.

PMID:
25449689

Supplemental Content

Loading ...
Support Center